ANKMY2 and autosomal dominant polycystic kidney disease: Our data confirms that the ANKMY2 and the adenylyl cyclase trafficking pathway is conserved in humans, making ANKMY2 a more compelling therapeutic target in ADPKD in reducing cystic burden.